KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...

US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...